Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine for hospitalized adults with COVID-19
IRCT20200426047206N3Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cyclosporine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Clinical outcome and prognosis of patients with COVID-19. Started Jul 2020; status: completed.
02
Drugs
cyclosporine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200426047206N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200426047206N3.